 NetScientific PLC LON:NSCI said an investee company will share additional data that will underline the potential efficacy of a breakthrough cancer immunotherapy. PDS Biotechnology Corporation NASDAQ:PDSB will use its presentation at the prestigious American Society of Clinical Oncology ASCO annual meeting next month to reveal it has observed a 10-out-of-14, or 71 response rate to lead drug PDS0101. 